Search

Your search keyword '"Piperno-Neumann S"' showing total 544 results
Start Over Author "Piperno-Neumann S"
544 results on '"Piperno-Neumann S"'

51. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

Author

Bellera, C. A., Penel, N., Ouali, M., Bonvalot, S., Casali, P. G., Nielsen, O. S., Delannes, M., Litière, S., Bonnetain, F., Dabakuyo, T. S., Benjamin, R. S., Blay, J.-Y., Bui, B. N., Collin, F., Delaney, T. F., Duffaud, F., Filleron, T., Fiore, M., Gelderblom, H., George, S., Grimer, R., Grosclaude, P., Gronchi, A., Haas, R., Hohenberger, P., Issels, R., Italiano, A., Jooste, V., Krarup-Hansen, A., Le Péchoux, C., Mussi, C., Oberlin, O., Patel, S., Piperno-Neumann, S., Raut, C., Ray-Coquard, I., Rutkowski, P., Schuetze, S., Sleijfer, S., Stoeckle, E., Van Glabbeke, M., Woll, P., Gourgou-Bourgade, S., and Mathoulin-Pélissier, S.

Published
2015
Full Text
View/download PDF

54. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

Author

European Society for Medical Oncology, Strauss, S. J., Frezza, Anna M., Abecassis, N., Bajpai, J., Bauer, Sebastian, Biagini, R., Bielack, S., Blay, Jean-Yves, Bolle, S., Bonvalot, Sylvie, Boukovinas, I., Bovee, J. V. M. G., Boye, K., Brennan, Bernadette, Brodowicz, T., Buonadonna, A., Álava, Enrique de, Dei Tos, Angelo Paolo, García del Muro, Xavier, Dufresne, Armelle, Eriksson, Mikael, Fagioli, F., Fedenko, Alexander, Ferraresi, Virginia, Ferrari, A., Gaspar, Nathalie, Gasperoni, Silvia, Gelderblom, Hans, Gouin, Francois, Grignani, Giovanni, Gronchi, Alesandro, Haas, R. L., Hassan, A. B., Hecker-Nolting, S., Hindi, Nadia, Hohenberger, Peter, Joensuu, Heikki, Jones, Robin L., Jungels, C., Jutte, P., Kager, L., Kasper, Bernd, Kawai, Akira, Kopeckova, K., Krákorová, D. A., Le Cesne, Axel, Le Grange, F., Legius, E., Leithner, Andreas, López-Pousa, Antonio, Martín-Broto, Javier, Merimsky, O., Messiou, C., Miah, A. B., Mir, Olivier, Montemurro, M., Morland, B., Morosi, Carlo, Palmerini, Emanuela, Pantaleo, M. A., Piana, R., Piperno-Neumann, S., Reichardt, Peter, Rutkowski, Piotr, Safwat, A. A., Sangalli, C., Sbaraglia, Marta, Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Sundby Hall, K., Trama, A., Unk, M., van de Sande, Michiel, van der Graaf, W. T., van Houdt, W. J., Frebourg, T., Ladenstein, Rudolf, Casali, Paolo G., Stacchiotti, Silvia, European Society for Medical Oncology, Strauss, S. J., Frezza, Anna M., Abecassis, N., Bajpai, J., Bauer, Sebastian, Biagini, R., Bielack, S., Blay, Jean-Yves, Bolle, S., Bonvalot, Sylvie, Boukovinas, I., Bovee, J. V. M. G., Boye, K., Brennan, Bernadette, Brodowicz, T., Buonadonna, A., Álava, Enrique de, Dei Tos, Angelo Paolo, García del Muro, Xavier, Dufresne, Armelle, Eriksson, Mikael, Fagioli, F., Fedenko, Alexander, Ferraresi, Virginia, Ferrari, A., Gaspar, Nathalie, Gasperoni, Silvia, Gelderblom, Hans, Gouin, Francois, Grignani, Giovanni, Gronchi, Alesandro, Haas, R. L., Hassan, A. B., Hecker-Nolting, S., Hindi, Nadia, Hohenberger, Peter, Joensuu, Heikki, Jones, Robin L., Jungels, C., Jutte, P., Kager, L., Kasper, Bernd, Kawai, Akira, Kopeckova, K., Krákorová, D. A., Le Cesne, Axel, Le Grange, F., Legius, E., Leithner, Andreas, López-Pousa, Antonio, Martín-Broto, Javier, Merimsky, O., Messiou, C., Miah, A. B., Mir, Olivier, Montemurro, M., Morland, B., Morosi, Carlo, Palmerini, Emanuela, Pantaleo, M. A., Piana, R., Piperno-Neumann, S., Reichardt, Peter, Rutkowski, Piotr, Safwat, A. A., Sangalli, C., Sbaraglia, Marta, Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Sundby Hall, K., Trama, A., Unk, M., van de Sande, Michiel, van der Graaf, W. T., van Houdt, W. J., Frebourg, T., Ladenstein, Rudolf, Casali, Paolo G., and Stacchiotti, Silvia

Published
2021

57. 1913O A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study

Author

Pautier, P., Italiano, A., Piperno-Neumann, S., Chevreau, C.M., Penel, N., Firmin, N., Rouquette, P. Boudou, Bertucci, F., Le Brun-Ly, V., Ray-Coquard, I.L., Kalbacher, E., Bompas, E., Collard, O., Isambert, N., Guillemet, C., Rios, M., Le Cesne, A., Archambaud, B., and Duffaud, F.

Published
2023
Full Text
View/download PDF

62. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

Author

European Organisation for Research and Treatment of Cancer, D’Ambrosio, Lorenzo, Touati, Nathan, Blay, Jean-Yves, Grignani, Giovanni, Flippot, Ronan, Czarnecka, Anna M., Piperno-Neumann, S., Martín-Broto, Javier, Sanfilippo, Roberta, Katz, Daniela, Duffaud, Florence, Vincenzi, Bruno, Stark, Daniel P., Mazzeo, Filomena, Tuchscherer, Armin, Chevreau, Christine, Sherriff, Jenny, Estival, Anna, Litiere, Saskia, Sents, Ward, Ray‐Coquard, Isabelle, Tolomeo, Francesco, Le Cesne, Axel, Rutkowski, Piotr, Stacchiotti, Silvia, Kasper, Bernd, Gelderblom, Hans, Gronchi, Alesandro, European Organisation for Research and Treatment of Cancer, D’Ambrosio, Lorenzo, Touati, Nathan, Blay, Jean-Yves, Grignani, Giovanni, Flippot, Ronan, Czarnecka, Anna M., Piperno-Neumann, S., Martín-Broto, Javier, Sanfilippo, Roberta, Katz, Daniela, Duffaud, Florence, Vincenzi, Bruno, Stark, Daniel P., Mazzeo, Filomena, Tuchscherer, Armin, Chevreau, Christine, Sherriff, Jenny, Estival, Anna, Litiere, Saskia, Sents, Ward, Ray‐Coquard, Isabelle, Tolomeo, Francesco, Le Cesne, Axel, Rutkowski, Piotr, Stacchiotti, Silvia, Kasper, Bernd, Gelderblom, Hans, and Gronchi, Alesandro

Abstract

[Background] The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype‐specific prospective controlled data lacking, this study retrospectively evaluated doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone as first‐line treatments for advanced/metastatic leiomyosarcoma treated at European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) sites., [Methods] The inclusion criteria were a confirmed histological diagnosis, treatment between January 2010 and December 2015, measurable disease (Response Evaluation Criteria in Solid Tumors 1.1), an Eastern Cooperative Oncology Group performance status ≤2, and an age ≥ 18 years. The endpoints were progression‐free survival (PFS), overall survival (OS), and overall response rate (ORR). PFS was analyzed with methods for interval‐censored data. Patients were matched according to their propensity scores, which were estimated with a logistic regression model accounting for histology, grade, age, sex, performance status, tumor site, and tumor extent., [Results] Three hundred three patients from 18 EORTC‐STBSG sites were identified. One hundred seventeen (39%) received doxorubicin plus dacarbazine, 71 (23%) received doxorubicin plus ifosfamide, and 115 (38%) received doxorubicin. In the 2:1:2 propensity score–matched population (205 patients), the estimated median PFS was 9.2 months (95% confidence interval [CI], 5.2‐9.7 months), 8.2 months (95% CI, 5.2‐10.1 months), and 4.8 months (95% CI, 2.3‐6.0 months) with ORRs of 30.9%, 19.5%, and 25.6% for doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone, respectively. PFS was significantly longer with doxorubicin plus dacarbazine versus doxorubicin (hazard ratio [HR], 0.72; 95% CI, 0.52‐0.99). Doxorubicin plus dacarbazine was associated with longer OS (median, 36.8 months; 95% CI, 27.9‐47.2 months) in comparison with both doxorubicin plus ifosfamide (median, 21.9 months; 95% CI, 16.7‐33.4 months; HR, 0.65; 95% CI, 0.40‐1.06) and doxorubicin (median, 30.3 months; 95% CI, 21.0‐36.3 months; HR, 0.66; 95% CI, 0.43‐0.99). Adjusted analyses retained an effect for PFS but not for OS. None of the factors selected for multivariate analysis had a significant interaction with the received treatment for both PFS and OS., [Conclusions] This is the largest retrospective study of first‐line treatment for advanced leiomyosarcoma. In the propensity score–matched population, doxorubicin and dacarbazine showed favorable activity in terms of both ORR and PFS and warrants further evaluation in prospective trials.

Published
2020

66. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group

Author

Pautier, P., Floquet, A., Gladieff, L., Bompas, E., Ray-Coquard, I., Piperno-Neumann, S., Selle, F., Guillemet, C., Weber, B., Largillier, R., Bertucci, F., Opinel, P., Duffaud, F., Reynaud-Bougnoux, A., Delcambre, C., Isambert, N., Kerbrat, P., Netter-Pinon, G., Pinto, N., Duvillard, P., Haie-Meder, C., Lhommé, C., and Rey, A.

Published
2013
Full Text
View/download PDF

69. 1636P METASYN: Patterns of care and outcomes of 387 METAstatic SYNovial sarcoma: Real-life data from the French Sarcoma Group (GSF/GETO)

Author

Moreau-Bachelard, C., primary, Toulmonde, M., additional, Le Cesne, A., additional, Brahmi, M., additional, Italiano, A., additional, Mir, O., additional, Piperno-Neumann, S., additional, Laurence, V., additional, Firmin, N., additional, Chevreau, C.M., additional, Bertucci, F., additional, Narciso, B., additional, Dubray-Longeras, P., additional, Delcambre, C., additional, Saada-Bouzid, E., additional, Soulié, P., additional, Perrin, C., additional, Blay, J-Y., additional, and Bompas, E., additional

Published
2020
Full Text
View/download PDF

70. 1650P Desmoid type fibromatosis in patients

Author

Bouttefroy, S., primary, Penel, N., additional, Minard-Colin, V., additional, Orbach, D., additional, Le Cesne, A., additional, Blay, J-Y., additional, Marec Berard, P., additional, Verité, C., additional, Laurence, V., additional, Piperno-Neumann, S., additional, Defachelles, A-S., additional, Bompas, E., additional, Chevreau, C.M., additional, Duffaud, F., additional, Salas, S., additional, Morelle, M., additional, Jean Denis, M., additional, Italiano, A., additional, Bonvalot, S., additional, and Corradini, N., additional

Published
2020
Full Text
View/download PDF

71. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)

Author

Pautier, P., primary, Penel, N., additional, Ray-Coquard, I., additional, Italiano, A., additional, Bompas, E., additional, Delcambre, C., additional, Bay, J.-O., additional, Bertucci, F., additional, Delaye, J., additional, Chevreau, C., additional, Cupissol, D., additional, Bozec, L., additional, Eymard, J.-C., additional, Saada, E., additional, Isambert, N., additional, Guillemet, C., additional, Rios, M., additional, Piperno-Neumann, S., additional, Chenuc, G., additional, and Duffaud, F., additional

Published
2020
Full Text
View/download PDF

72. Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer

Author

Piperno-Neumann, S., Piulats, J.M., Goebeler, M., Galloway, I., Lugowska, I., Becker, J.C., Vihinen, P., Calster, J. van, Hadjistilianou, T., Proenca, R., Caminal, J.M., Rogasik, M., Blay, J.Y., Kapiteijn, E., and EURACAN Network

Subjects
Oncology, Cancer Research, Poor prognosis, medicine.medical_specialty, Referral, Immune checkpoint inhibitors, Medizin, European Reference Network, lcsh:RC254-282, Metastasis, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, rare cancer, uveal melanoma, Melanoma, Iris (Ull), Iris (Eye), business.industry, Ophthalmopathies, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Rare cancer, Access to information, 030220 oncology & carcinogenesis, Cutaneous melanoma, Perspective, 030221 ophthalmology & optometry, business, Oftalmopaties
Abstract

Uveal melanoma (UM) is the most frequent primary ocular cancer in adults, accounting for 5% of all melanomas. Despite effective treatments for the primary tumour, up to 50% of UM patients will develop metastasis, leading to a very poor prognosis and a median overall survival of 6 to 12 months, with no major improvements in the last 30 years. There is no standard oncological treatment available for metastatic UM patients, and BRAF/MEK and immune checkpoint inhibitors show disappointing results when compared to cutaneous melanoma (CM). Recent advances in biology, however, identified specific gene and chromosome alterations, potentially permitting an actively tailored surveillance strategy, and dedicated clinical studies. Being a rare cancer, UM patients have to overcome issues such as identifying referral centres, having access to information, and partnering with oncologists for specific management strategies and research priorities. Here, we describe how the European Rare Adult solid Cancer Network (EURACAN) will help in addressing these challenges and accelerating international collaborations to enhance the development of innovative treatments in UM.

Published
2019

74. Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.

Author

Pautier, P., Italiano, A., Piperno-Neumann, S., Chevreau, C., Penel, N., Firmin, N., Boudou-Rouquette, P., Bertucci, F., Lebrun-Ly, V., Ray-Coquard, I., Kaibacher, E., Bompas, E., Collard, O., Isambert, N., Guillemet, C., Rios, M., Le Cesne, A., Balleyguier, C., Archambaud, B., and Duffaud, F.

Subjects
*TRABECTEDIN, *LEIOMYOSARCOMA, *PROGRESSION-free survival, *CLINICAL trials, *OVERALL survival
Abstract

BACKGROUND: The addition of trabectedin to doxorubicin, followed by trabectedin maintenance, may have superior efficacy to doxorubicin alone as first-line treatment in patients with advanced leiomyosarcoma. METHODS: We conducted a phase 3 trial involving patients with metastatic or unresectable leiomyosarcoma who had not received chemotherapy previously. Patients were randomly assigned to receive either single-agent doxorubicin (six cycles) or doxorubicin plus trabectedin (six cycles), with continued trabectedin as maintenance therapy in patients in the doxorubicin-trabectedin group who did not have disease progression. Surgery to resect residual disease was allowed in each group after six cycles of therapy. Analyses of progression-free survival (primary end point) and overall survival (secondary end point) were adjusted for two stratification factors: tumor origin site (uterine vs. soft tissue) and disease stage (locally advanced vs. metastatic). The primary end-point results were reported previously. RESULTS: A total of 150 patients underwent randomization. At a median follow-up of 55 months (interquartile range, 49 to 63), a total of 107 patients had died (47 in the doxorubicintrabectedin group and 60 in the doxorubicin group). The median overall survival was longer in the doxorubicin-trabectedin group (33 months; 95% confidence interval [CI], 26 to 48) than in the doxorubicin group (24 months; 95% CI, 19 to 31); the adjusted hazard ratio for death was 0.65 (95% CI, 0.44 to 0.95). In a finding consistent with earlier reports, progression-free survival was longer in the doxorubicin-trabectedin group (12 months; 95% CI, 10 to 16) than in the doxorubicin group (6 months; 95% CI, 4 to 7); the adjusted hazard ratio for progression or death was 0.37 (95% CI, 0.26 to 0.53). The incidence of adverse events and the percentage of patients with dose reductions were higher with doxorubicin plus trabectedin than with doxorubicin alone. CONCLUSIONS: Combination therapy with doxorubicin and trabectedin induction, followed by trabectedin maintenance, was associated with improved overall survival and progression-free survival, as compared with doxorubicin alone, among patients with metastatic or surgically unresectable uterine or soft-tissue leiomyosarcoma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

75. Actualisation des recommandations de prise en charge du mélanome stade I à III

Author

X. Mirabel, De Raucourt S, R. Vanwijck, Jean-François Emile, M.G. Denis, De La Fouchardiere A, Sophie Dalac, Bernard Guillot, Elif Hindié, Nathalie Lassau, Piperno Neumann S, Thomas Jouary, and Alain Dupuy

Subjects
Cancer Research, business.industry, Melanoma, Sentinel lymph node, Hematology, General Medicine, medicine.disease, Proto-Oncogene Proteins B-raf, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Text mining, Oncology, 030220 oncology & carcinogenesis, Genotype, medicine, Cancer research, Radiology, Nuclear Medicine and imaging, Neoplasm staging, business
Published
2016

76. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg 51, 2018)

Author

Casali, P.G., Abecassis, N., Aro, H.T., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Brodovvicz, T., Broto, J.M., Buonadonna, A., Alava, E. de, Tos, A.P.D., Muro, X.G. del, Dileo, P., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., Ferrari, S., Frezza, A.M., Gasperoni, S., Gelderblom, H., Gil, T., Grignani, G., Gronchi, A., Haas, R.L., Hassan, B., Hohenberger, P., Lssels, R., Joensuu, H., Jones, R.L., Judson, I., Jutte, P., Kaal, S., Kasper, B., Kopeckova, K., Krakorova, D.A., Cesne, A. le, Lugowska, I., Merimsky, O., Montemurro, M., Pantaleo, M.A., Piana, R., Picci, P., Piperno-Neumann, S., Pousa, A.L., Reichardt, P., Robinson, M.H., Rutkovvski, P., Safwat, A.A., Schoffski, P., Sleijfer, S., Stacchiotti, S., Hall, K.S., Unk, M., Coevorden, F. van, Graaf, W.T.A. van der, Whelan, J., Wardelmann, E., Zaikova, O., Blay, J.Y., ESMO Guidelines Comm, and EURACAN

Published
2018

77. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, P G, Abecassis, N, Aro, H T, Bauer, S, Biagini, R, Bielack, S, Bonvalot, S, Boukovinas, I, Bovee, J V M G, Brodowicz, T, Broto, J M, Buonadonna, A, De Álava, E, Dei Tos, A P, Del Muro, X G, Dileo, P, Eriksson, M, Fedenko, A, Ferraresi, V, Ferrari, A, Ferrari, S, Frezza, A M, Gasperoni, S, Gelderblom, H, Gil, T, Grignani, G, Gronchi, A, Haas, R L, Hassan, B, Hohenberger, P, Issels, R, Joensuu, H, Jones, R L, Judson, I, Jutte, P, Kaal, S, Kasper, B, Kopeckova, K, Krákorová, D A, Le Cesne, A, Lugowska, I, Merimsky, O, Montemurro, M, Pantaleo, M A, Piana, R, Picci, P, Piperno-Neumann, S, Pousa, A L, Reichardt, P, and Safwat, A A

Published
2018

78. Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts)

Author

Penel, N., primary, Blay, J.-Y., additional, Wallet, J., additional, Mir, O., additional, Italiano, A., additional, Bertucci, F., additional, Piperno-Neumann, S., additional, Brodowicz, T., additional, Bompas, E., additional, Liegl-Atzwanger, B., additional, Chevreau, C.M., additional, Ray-Coquard, I.L., additional, Taieb, S., additional, Decoupigny, E., additional, Deley, M C Le, additional, and Le Cesne, A., additional

Published
2019
Full Text
View/download PDF

79. Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients

Author

Saint-Ghislain, M., primary, Geoffrois, L., additional, Gastaud, L., additional, Lesimple, T., additional, Negrier, S., additional, Penel, N., additional, Kurtz, J.-E., additional, Le Corre, Y., additional, Gardrat, S., additional, Barnhill, R., additional, Cassoux, N., additional, Mariani, P., additional, Servois, V., additional, Piperno-Neumann, S., additional, and Rodrigues, M., additional

Published
2019
Full Text
View/download PDF

80. Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER

Author

Duffaud, F., primary, Blay, J.-Y., additional, Italiano, A., additional, Bompas, E., additional, Rios, M., additional, Penel, N., additional, Mir, O., additional, Piperno-Neumann, S., additional, Chevreau, C.M., additional, Delcambre, C., additional, Bertucci, F., additional, Boudou Rouquette, P., additional, Vegas, H., additional, Perrin, C., additional, Thyss, A., additional, Schiffler, C., additional, Monard, L., additional, Bouvier, C., additional, Vidal, V., additional, and Chabaud, S., additional

Published
2019
Full Text
View/download PDF

81. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Author

Pivot, Xavier, primary, Romieu, Gilles, additional, Debled, Marc, additional, Pierga, Jean-Yves, additional, Kerbrat, Pierre, additional, Bachelot, Thomas, additional, Lortholary, Alain, additional, Espié, Marc, additional, Fumoleau, Pierre, additional, Serin, Daniel, additional, Jacquin, Jean-Philippe, additional, Jouannaud, Christelle, additional, Rios, Maria, additional, Abadie-Lacourtoisie, Sophie, additional, Venat-Bouvet, Laurence, additional, Cany, Laurent, additional, Catala, Stéphanie, additional, Khayat, David, additional, Gambotti, Laetitia, additional, Pauporté, Iris, additional, Faure-Mercier, Celine, additional, Paget-Bailly, Sophie, additional, Henriques, Julie, additional, Grouin, Jean Marie, additional, Piprot, C, additional, Cals, L, additional, Chaigneau, L, additional, Demarchi, F, additional, N'Guyen, T, additional, Stein, U, additional, Villanueva, C, additional, Bréau, JL, additional, Chouahnia, AK, additional, Saintigny, P, additional, Boué, F, additional, deSaint-Hilaire, P, additional, Guimont, I, additional, Grossat, N, additional, Valenza, B, additional, Lévy, E, additional, Médioni, J, additional, Delbaldo, C, additional, Grenier, J, additional, Pouessel, D, additional, Lavau-Denès, S, additional, Falandry, C, additional, Fournel-Fédérico, C, additional, Freyer, G, additional, Tartas, S, additional, Trillet-Lenoir, V, additional, Bons, F, additional, Auclerc, G, additional, Chièze, S, additional, Raban, N, additional, Tournigand, C, additional, Trager-Maury, S, additional, Bousquet, G, additional, Cuvier, C, additional, Giacchetti, S, additional, Hocini, A, additional, LeMaignan, C, additional, Misset, JL, additional, Avenin, D, additional, Beerblock, C, additional, Gligorov, J, additional, Rivera, P, additional, Roché, H, additional, Bougnoux, P, additional, Hajjaji, N, additional, Capitain, O, additional, Delva, R, additional, Maillart, P, additional, Soulié, P, additional, Bonnefoi, H, additional, Durand, M, additional, Madranges, N, additional, Mauriac, L, additional, Chollet, P, additional, Dillies, AF, additional, Durando, X, additional, Ferrière, JP, additional, Mouret-Reynier, C, additional, Nabholtz, JM, additional, Van Praagh, I, additional, Cottu, P, additional, Diéras, V, additional, Durieux, A, additional, Galotte, M, additional, Girre, V, additional, Henry, S, additional, Iurisci, I, additional, Jouve, M, additional, Laurence, V, additional, Mignot, L, additional, Piperno-Neumann, S, additional, Tresca, P, additional, Coudert, B, additional, Ferrant, E, additional, Mayer, F, additional, Vanneuville, AC, additional, Bonneterre, J, additional, Servent, V, additional, Vanlemmens, L, additional, Vennin, P, additional, Guastalla, JP, additional, Biron, P, additional, Dupuy-Brousseau, L, additional, Lancry, L, additional, Ray-Coquard, I, additional, Rebattu, P, additional, Trédan, O, additional, Extra, JM, additional, Rousseau, F, additional, Tarpin, C, additional, Fabbro, M, additional, Luporsi, E, additional, Uwer, L, additional, Weber, B, additional, Berton-Rigaud, D, additional, Bourbouloux, E, additional, Campone, M, additional, Ferrero, JM, additional, Follana, P, additional, Largillier, R, additional, Mari, V, additional, Costa, B, additional, Curé, H, additional, Eymard, JC, additional, Jovenin, N, additional, Lebrun, D, additional, Meunier, J, additional, Yazbek, G, additional, Gedoin, D, additional, Laguerre, B, additional, Lefeuvre, C, additional, Vauléon, E, additional, Chevrier, A, additional, Guillemet, C, additional, Leheurteur, M, additional, Rigal, O, additional, Tennevet, I, additional, Veyret, C, additional, Brain, E, additional, Guiterrez, M, additional, Mefti-Lacheraf, F, additional, Petit, T, additional, Dalenc, F, additional, Gladieff, L, additional, André, F, additional, Delaloge, S, additional, Domont, J, additional, Ezenfis, J, additional, Spielmann, M, additional, Guillet, P, additional, Boulanger, V, additional, Provençal, J, additional, Stefani, L, additional, Alliot, C, additional, Ré, D, additional, Bellaiche-Miccio, C, additional, Boutan-Laroze, G, additional, Vanica, R, additional, Dion, P, additional, Sadki-Benaoudia, G, additional, Marti, A, additional, Villing, AL, additional, Slama, B, additional, Dutel, JL, additional, Nguyen, S, additional, Saad, R, additional, Arsène, O, additional, Merad-Boudia, Z, additional, Orfeuvre, H, additional, Egreteau, J, additional, Goudier, MJ, additional, Lamy, R, additional, Leduc, B, additional, Sarda, C, additional, Salles, B, additional, Agostini, C, additional, Cauvin, I, additional, Dufresne, A, additional, Mangold, M, additional, Lebouvier-Sadot, S, additional, Audhuy, B, additional, Barats, JC, additional, Cluet-Dennetière, S, additional, Zylberait, D, additional, Netter, G, additional, Gautier-Felizot, L, additional, Cojean-Zelek, I, additional, Plantade, A, additional, Vignot, S, additional, Guardiola, E, additional, Marti, P, additional, deHartingh, I, additional, Diab, R, additional, Dietmann, A, additional, Ruck, S, additional, Portois, C, additional, Oddou-Lagranière, S, additional, Campos-Gazeau, F, additional, Bourcier, A, additional, Priou, F, additional, Geay, JF, additional, Mayeur, D, additional, Gabez, P, additional, ElAmarti, R, additional, Combe, M, additional, Raichon-Patru, P, additional, Amsalhem, P, additional, Dauba, J, additional, Paraiso, D, additional, Guinet, F, additional, Duvert, B, additional, Litor, M, additional, Kara-Slimane, F, additional, Bichoffe, A, additional, Denizon, N, additional, Soyer, P, additional, Morvan, F, additional, Van-Hulst, S, additional, Vincent, L, additional, Alleaume, C, additional, Ibanez-Martin, P, additional, Youssef, A, additional, Tadrist, Z, additional, Carola, E, additional, Pourny, C, additional, Toccanier, JF, additional, Al-Aukla, N, additional, Mahour-Bacha, K, additional, Salvat, J, additional, Nouyrigat, P, additional, Clippe, S, additional, Gouttebel, MC, additional, Vedrine, L, additional, Clavreul, G, additional, Collard, O, additional, Mille, D, additional, Goubely, Y, additional, Hervé, R, additional, Kirscher, S, additional, Plat, F, additional, Delecroix, V, additional, Ligeza-Poisson, V, additional, Coeffic, D, additional, Fric, D, additional, Garnier, C, additional, Leyronnas, C, additional, Kreitman, T, additional, Teissier, E, additional, Martin, P, additional, Rohart deCordoue, S, additional, ElKouri, C, additional, Ramée, JF, additional, Laporte, C, additional, Bernard, O, additional, Altwegg, T, additional, Darut-Jouve, A, additional, Dujols, JP, additional, Darloy, F, additional, Giraud, C, additional, Pottier-Kyndt, V, additional, Achour, N, additional, Drony, S, additional, Moriceau, M, additional, Sarrazin, C, additional, Legueul, JC, additional, Mandet, J, additional, Besson, D, additional, Hardy-Bessard, AC, additional, Cretin, J, additional, Houyau, P, additional, Achille, E, additional, Genêt, D, additional, Thévenot, H, additional, Moran-Ribon, A, additional, Pavlovitch, JM, additional, Ardisson, P, additional, Moullet, I, additional, Couderc, B, additional, Fichet, V, additional, Burki, F, additional, Auliard, A, additional, Levaché, CB, additional, Cailleux, P, additional, Schaeffer, F, additional, Albin, N, additional, Sévin-Robiche, D, additional, Domas, J, additional, Ellis, S, additional, Montcuquet, P, additional, Baumont, GA, additional, Bégue, M, additional, Gréget, S, additional, Ratoanina, JL, additional, Vanoli, A, additional, Bielsa, C, additional, Bonichon-Lamichhane, M, additional, Jaubert, D, additional, Laharie-Mineur, H, additional, Alcaraz, L, additional, Legouffe, E, additional, Bourgeois, H, additional, Cartron, G, additional, Denis, F, additional, Dupuis, O, additional, Ganem, G, additional, Roche-Forestier, S, additional, Delzenne, L, additional, Chirat, E, additional, Baticle, JL, additional, Béguier, E, additional, Jacquot, S, additional, Janssen, E, additional, Lauché, H, additional, LeRol, A, additional, Chantelard, JP, additional, L'Helgoualc'h, GA, additional, Antoine, EC, additional, Kanoui, A, additional, Llory, JF, additional, Vannetzel, JM, additional, Vignoud, J, additional, Bruna, C, additional, Facchini, T, additional, Moutel-Corviole, K, additional, Voloch, A, additional, Ghoul, A, additional, Loiseau, D, additional, Barbet, N, additional, Dohollou, N, additional, and Yakendji, K, additional

Published
2019
Full Text
View/download PDF

82. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author

Casali, Paolo G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, Sebastian, Biagini, R., Bonvalot, Sylvie, Boukovinas, I., Bovee, J. V. M. G., Brennan, Bernadette, Brodowicz, T., Martín-Broto, Javier, Brugières, L., Buonadonna, A., Álava, Enrique de, Dei Tos, Angelo Paolo, García del Muro, Xavier, Dileo, P., Dhooge, C., Eriksson, Mikael, Fagioli, F., Fedenko, Alexander, Ferraresi, Virginia, Ferrari, A., Frezza, Anna M., Gaspar, Nathalie, Gasperoni, Silvia, Gelderblom, Hans, Gil, T., Grignani, Giovanni, Gronchi, Alesandro, Haas, R. L., Hassan, B., Hecker-Nolting, S., Hohenberger, Peter, Issels, R., Joensuu, Heikki, Jones, Robin L., Judson, I., Jutte, P., Kaal, S., Kager, L., Kasper, Bernd, Kopeckova, K., Krákorová, D. A., Ladenstein, Rudolf, Le Cesne, Axel, Lugowska, Iwona, Merimsky, O., Montemurro, M., Morland, B., Pantaleo, M. A., Piana, R., Picci, Piero, Piperno-Neumann, S., Pousa, A. L., Reichardt, Peter, Robinson, M. H., Rutkowski, Piotr, Safwat, A. A., Schöffski, P., Sleijfer, S., Stacchiotti, Silvia, Strauss, Sandra, Sundby Hall, K., Unk, M., van Coevorden, F., van der Graaf, W. T., Whelan, Jeremy, Wardelmann, Eva, Zaikova, O., Blay, Jean-Yves, Casali, Paolo G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, Sebastian, Biagini, R., Bonvalot, Sylvie, Boukovinas, I., Bovee, J. V. M. G., Brennan, Bernadette, Brodowicz, T., Martín-Broto, Javier, Brugières, L., Buonadonna, A., Álava, Enrique de, Dei Tos, Angelo Paolo, García del Muro, Xavier, Dileo, P., Dhooge, C., Eriksson, Mikael, Fagioli, F., Fedenko, Alexander, Ferraresi, Virginia, Ferrari, A., Frezza, Anna M., Gaspar, Nathalie, Gasperoni, Silvia, Gelderblom, Hans, Gil, T., Grignani, Giovanni, Gronchi, Alesandro, Haas, R. L., Hassan, B., Hecker-Nolting, S., Hohenberger, Peter, Issels, R., Joensuu, Heikki, Jones, Robin L., Judson, I., Jutte, P., Kaal, S., Kager, L., Kasper, Bernd, Kopeckova, K., Krákorová, D. A., Ladenstein, Rudolf, Le Cesne, Axel, Lugowska, Iwona, Merimsky, O., Montemurro, M., Morland, B., Pantaleo, M. A., Piana, R., Picci, Piero, Piperno-Neumann, S., Pousa, A. L., Reichardt, Peter, Robinson, M. H., Rutkowski, Piotr, Safwat, A. A., Schöffski, P., Sleijfer, S., Stacchiotti, Silvia, Strauss, Sandra, Sundby Hall, K., Unk, M., van Coevorden, F., van der Graaf, W. T., Whelan, Jeremy, Wardelmann, Eva, Zaikova, O., and Blay, Jean-Yves

Published
2018

83. Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017

Author

Blay, J.-Y., primary, Toulmonde, M., additional, Penel, N., additional, Mir, O., additional, Chevreau, C.M., additional, Anract, P., additional, Bompas, E., additional, Rios, M., additional, Firmin, N., additional, Italiano, A., additional, Piperno-Neumann, S., additional, Kurtz, J.-E., additional, Duffaud, F., additional, Rosset, P., additional, Bertucci, F., additional, Perrin, C., additional, Chemin, C., additional, Ducimetiere, F., additional, Gouin, F., additional, and Le Cesne, A., additional

Published
2018
Full Text
View/download PDF

84. Corrections to “Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”

Author

Casali, P.G., primary, Abecassis, N., additional, Aro, H.T., additional, Bauer, S., additional, Biagini, R., additional, Bielack, S., additional, Bonvalot, S., additional, Boukovinas, I., additional, Bovee, J V M G, additional, Brodowicz, T., additional, Broto, J.M., additional, Buonadonna, A., additional, De Álava, E., additional, Dei Tos, A.P., additional, Del Muro, X.G., additional, Dileo, P., additional, Eriksson, M., additional, Fedenko, A., additional, Ferraresi, V., additional, Ferrari, A., additional, Ferrari, S., additional, Frezza, A.M., additional, Gasperoni, S., additional, Gelderblom, H., additional, Gil, T., additional, Grignani, G., additional, Gronchi, A., additional, Haas, R.L., additional, Hassan, B., additional, Hohenberger, P., additional, Issels, R., additional, Joensuu, H., additional, Jones, R.L., additional, Judson, I., additional, Jutte, P., additional, Kaal, S., additional, Kasper, B., additional, Kopeckova, K., additional, Krákorová, D.A., additional, Le Cesne, A., additional, Lugowska, I., additional, Merimsky, O., additional, Montemurro, M., additional, Pantaleo, M.A., additional, Piana, R., additional, Picci, P., additional, Piperno-Neumann, S., additional, Pousa, A.L., additional, Reichardt, P., additional, Robinson, M.H., additional, Rutkowski, P., additional, Safwat, A.A., additional, Schöffski, P., additional, Sleijfer, S., additional, Stacchiotti, S., additional, Sundby Hall, K., additional, Unk, M., additional, Van Coevorden, F., additional, van der Graaf, W.T.A., additional, Whelan, J., additional, Wardelmann, E., additional, Zaikova, O., additional, and Blay, J.Y., additional

Published
2018
Full Text
View/download PDF

85. Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: A French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study

Author

Italiano, A., primary, Penel, N., additional, Toulmonde, M., additional, Bompas, E., additional, Piperno-Neumann, S., additional, Pulido, M., additional, Entz-Werle, N., additional, Le Cesne, A., additional, Chevreau, C.M., additional, Duffaud, F., additional, Ray-Coquard, I.L., additional, Bellera, C., additional, Mathoulin-Pelissier, S., additional, and Blay, J.-Y., additional

Published
2018
Full Text
View/download PDF

86. Corrections to “Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”

Author

Casali, P.G., primary, Abecassis, N., additional, Aro, H.T., additional, Bauer, S., additional, Biagini, R., additional, Bielack, S., additional, Bonvalot, S., additional, Boukovinas, I., additional, Bovee, J V M G, additional, Brodowicz, T., additional, Broto, J.M., additional, Buonadonna, A., additional, De Álava, E., additional, Dei Tos, A.P., additional, Del Muro, X.G., additional, Dileo, P., additional, Eriksson, M., additional, Fedenko, A., additional, Ferraresi, V., additional, Ferrari, A., additional, Ferrari, S., additional, Frezza, A.M., additional, Gasperoni, S., additional, Gelderblom, H., additional, Gil, T., additional, Grignani, G., additional, Gronchi, A., additional, Haas, R.L., additional, Hassan, B., additional, Hohenberger, P., additional, Issels, R., additional, Joensuu, H., additional, Jones, R.L., additional, Judson, I., additional, Jutte, P., additional, Kaal, S., additional, Kasper, B., additional, Kopeckova, K., additional, Krákorová, D.A., additional, Le Cesne, A., additional, Lugowska, I., additional, Merimsky, O., additional, Montemurro, M., additional, Pantaleo, M.A., additional, Piana, R., additional, Picci, P., additional, Piperno-Neumann, S., additional, Pousa, A.L., additional, Reichardt, P., additional, Robinson, M.H., additional, Rutkowski, P., additional, Safwat, A.A., additional, Schöffski, P., additional, Sleijfer, S., additional, Stacchiotti, S., additional, Sundby Hall, K., additional, Unk, M., additional, Van Coevorden, F., additional, van der Graaf, W.T.A., additional, Whelan, J., additional, Wardelmann, E., additional, Zaikova, O., additional, and Blay, J.Y., additional

Published
2018
Full Text
View/download PDF

87. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients

Author

Peters, S., Voelter, V., Zografos, L., Pampallona, S., Popescu, R., Gillet, M., Bosshard, W., Fiorentini, G., Lotem, M., Weitzen, R., Keilholz, U., Humblet, Y., Piperno-Neumann, S., Stupp, R., Leyvraz, S., Peters, S., Voelter, V., Zografos, L., Pampallona, S., Popescu, R., Gillet, M., Bosshard, W., Fiorentini, G., Lotem, M., Weitzen, R., Keilholz, U., Humblet, Y., Piperno-Neumann, S., Stupp, R., and Leyvraz, S.

Abstract

Background: Exclusive liver metastases occur in up to 40% of patients with uveal melanoma associated with a median survival of 2-7 months. Single agent response rates with commonly available chemotherapy are below 10%. We have investigated the use of fotemustine via direct intra-arterial hepatic (i.a.h.) administration in patients with uveal melanoma metastases. Patients and methods: A total of 101 patients from seven centers were treated with i.a.h. fotemustine, administered intra-arterially weekly for a 4-week induction period, and then as a maintenance treatment every 3 weeks until disease progression, unacceptable toxicity or patient refusal. Results: A median of eight fotemustine infusions per patient were delivered (range 1-26). Catheter related complications occurred in 23% of patients; however, this required treatment discontinuation in only 10% of the patients. The overall response rate was 36% with a median overall survival of 15 months and a 2-year survival rate of 29%. LDH, time between diagnosis and treatment start and gender were significant predictors of survival. Conclusions: Locoregional treatment with fotemustine is well tolerated and seems to improve outcome of this poor prognosis patient population. Median survival rates are among the longest reported and one-third of the patients are still alive at 2 years

Published
2017

88. Results of the LMS03 phase II study evaluating gemcitabine combined with pazopanib as a 2nd-line treatment for metastatic/relapsed leiomyosarcomas (uterine or soft tissue) after failure of anthracycline-based chemotherapy: The UNICANCER SARCOME 11 study

Author

Pautier, P., primary, Penel, N., additional, Ray-Coquard, I., additional, Italiano, A., additional, Bompas, E., additional, Delcambre, C., additional, Bay, J-O., additional, Bertucci, F., additional, Delaye, J., additional, Chevreau, C., additional, Cupissol, D., additional, Le Moal, L. Bozec, additional, Eymard, J-C., additional, Thyss, A., additional, Isambert, N., additional, Guillemet, C., additional, Rios, M., additional, Piperno-Neumann, S., additional, Chenuc, G., additional, and Duffaud, F., additional

Published
2017
Full Text
View/download PDF

89. Localized undifferentiated endometrial sarcomas (LUES): Results of a French Sarcoma Group (FSG) retrospective series of 39 patients (pts)

Author

Meurer, M., primary, Duffaud, F., additional, Salas, S., additional, Bertucci, F., additional, Floquet, A., additional, Penel, N., additional, Ray-Coquard, I., additional, Italiano, A., additional, Blay, J-Y., additional, Pautier, P., additional, Delannes, M., additional, Piperno-Neumann, S., additional, Mancini, J., additional, and Auriche, M., additional

Published
2017
Full Text
View/download PDF

90. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide and cisplatin (API), followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). Update at 10 years

Author

Pautier, P., primary, Brard, C., additional, Floquet, A., additional, Gladieff, L., additional, Rios, M., additional, Piperno-Neumann, S., additional, Berton-Rigaud, D., additional, Blay, J.-Y., additional, Fabbro, M., additional, Lotz, J.-P., additional, Vinceneux, A., additional, Bertucci, F., additional, De La Motte Rouge, T., additional, Guillemet, C., additional, Genestie, C., additional, and Duffaud, F., additional

Published
2017
Full Text
View/download PDF

92. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

Author

Carita, G., primary, Frisch-Dit-Leitz, E., additional, Dahmani, A., additional, Raymondie, C., additional, Cassoux, N., additional, Piperno-Neumann, S., additional, Némati, F., additional, Laurent, C., additional, De Koning, L., additional, Halilovic, E., additional, Jeay, S., additional, Wylie, A., additional, and Emery, C., additional

Published
2016
Full Text
View/download PDF

93. LBA88 - Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER

Author

Duffaud, F., Blay, J.-Y., Italiano, A., Bompas, E., Rios, M., Penel, N., Mir, O., Piperno-Neumann, S., Chevreau, C.M., Delcambre, C., Bertucci, F., Boudou Rouquette, P., Vegas, H., Perrin, C., Thyss, A., Schiffler, C., Monard, L., Bouvier, C., Vidal, V., and Chabaud, S.

Published
2019
Full Text
View/download PDF

97. Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS)

Author

Kotecki, N., primary, Le Cesne, A., additional, Tresch-Bruneel, E., additional, Mir, O., additional, Chevreau, C., additional, Bertucci, F., additional, Delcambre, C., additional, Saada-Bouzid, E., additional, Piperno-Neumann, S., additional, Bay, J.-O., additional, Ray-Coquard, I.L., additional, Ryckewaert, T., additional, Isambert, N., additional, Italiano, A., additional, Clisant, S., additional, Blay, J.-Y., additional, and Penel, N., additional

Published
2016
Full Text
View/download PDF

98. Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS)

Author

Le Cesne, A., primary, Blay, J.-Y., additional, Cupissol, D., additional, Italiano, A., additional, Delcambre, C., additional, Penel, N., additional, Isambert, N., additional, Chevreau, C., additional, Bompas, E., additional, Bertucci, F., additional, Chaigneau, L., additional, Piperno-Neumann, S., additional, Salas, S., additional, Rios, M., additional, Guillemet, C., additional, Bay, J.-O., additional, Ray-Coquard, I.L., additional, Mir, O., additional, Haddag, L., additional, and Foulon, S., additional

Published
2016
Full Text
View/download PDF

99. The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment

Author

Blay, J.-Y., primary, Le Cesne, A., additional, Penel, N., additional, Bompas, E., additional, Chevreau, C., additional, Duffaud, F., additional, Rios, M., additional, Kerbrat, P., additional, Cupissol, D., additional, Anract, P., additional, Kurtz, J.-E., additional, Lebbe, C., additional, Bertucci, F., additional, Piperno-Neumann, S., additional, Rosset, P., additional, Isambert, N., additional, Dubray-Longeras, P., additional, Ducimetière, F., additional, Coindre, J.-M., additional, and Italiano, A., additional

Published
2016
Full Text
View/download PDF

100. UM Cure 2020 - A consortium of European experts in uveal melanoma to identify new therapies for patients with metastatic disease

Author

Coupland, S., primary, Kalirai, H., additional, Jager, M., additional, Jochemsen, A.G., additional, van der Velden, P.A., additional, Snaar-Jagalska, B.E., additional, Dhomen, N., additional, Marais, R., additional, Romanowska Dixon, B., additional, Elas, M., additional, Mione, M.C., additional, Valente, A., additional, Ryll, B., additional, Ruijtenbeek, R., additional, Prestat, A., additional, Hafsi, H., additional, Barnhill, R., additional, Cassoux, N., additional, Decaudin, D., additional, Lantz, O., additional, Piperno-Neumann, S., additional, Stern, M.H., additional, and Roman-Roman, S., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results